1
|
Verdu-Rotellar JM, Vaillant-Roussel H, Abellana R, Jevsek LG, Assenova R, Lazic DK, Torsza P, Glynn LG, Lingner H, Demurtas J, Borgström B, Gibot-Boeuf S, Muñoz MA. Precipitating factors of heart failure decompensation, short-term morbidity and mortality in patients attended in primary care. Scand J Prim Health Care 2020; 38:473-480. [PMID: 33201746 PMCID: PMC7782727 DOI: 10.1080/02813432.2020.1844387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
OBJECTIVE To evaluate the precipitating factors for heart failure decompensation in primary care and associations with short-term prognosis. Design Prospective cohort study with a 30-d follow-up from an index consultation. Regression models to determine independent factors associated with hospitalisation or death. SETTING Primary care in ten European countries. Patients Patients with diagnosis of heart failure attended in primary care for a heart failure decompensation (increase of dyspnoea, unexplained weight gain or peripheral oedema). MAIN OUTCOME MEASURES Potential precipitating factors for decompensation of heart failure and their association with the event of hospitalisation or mortality 30 d after a decompensation. RESULTS Of 692 patients 54% were women, mean age 81 (standard deviation [SD] 8.9) years; mean left ventricular ejection fraction (LVEF) 55% (SD 12%). Most frequently identified heart failure precipitation factors were respiratory infections in 194 patients (28%), non-compliance of dietary recommendations in 184 (27%) and non-compliance with pharmacological treatment in 157 (23%). The two strongest precipitating factors to predict 30 d hospitalisation or death were respiratory infections (odds ratio [OR] 2.8, 95% confidence interval [CI] (2.4-3.4)) and atrial fibrillation (AF) > 110 beats/min (OR 2.2, CI 1.5-3.2). Multivariate analysis confirmed the association between the following variables and hospitalisation/death: In relation to precipitating factors: respiratory infection (OR 1.19, 95% CI 1.14-1.25) and AF with heart rate > 110 beats/min (OR 1.22, 95% CI 1.10-1.35); and regarding patient characteristics: New York Heart Association (NYHA) III or IV (OR 1.22, 95% CI 1.15-1.29); previous hospitalisation (OR 1.15, 95% CI 1.11-1.19); and LVEF < 40% (OR 1.14, 95% CI 1.09-1.19). CONCLUSIONS In primary care, respiratory infections and rapid AF are the most important precipitating factors for hospitalisation and death within 30 d following an episode of heart failure decompensation. Key points Hospitalisation due to heart failure decompensation represents the highest share of healthcare costs for this disease. So far, no primary care studies have analysed the relationship between precipitating factors and short term prognosis of heart failure decompensation episodes. We found that in 692 patients with heart failure decompensation in primary care, the respiratory infection and rapid atrial fibrillation (AF) increased the risk of short-term hospital admission or death. Patients with a hospital admission the previous year and a decompensation episode caused by respiratory infection were even more likely to be hospitalized or die within 30 d.
Collapse
Affiliation(s)
- José María Verdu-Rotellar
- Institut Català de la Salut, Barcelona, Spain
- Unitat de Suport a la Recerca de Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
- School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
- CONTACT José María Verdu-Rotellar Departament de Salut, Unitat de Suport a la Recerca, Gerència Territorial de Barcelona, Institut Català de la Salut-IDIAP Jordi Gol, | Generalitat de Catalunya Carrer Sardenya, 375 Entlo, Barcelona08025, Spain
| | - Helene Vaillant-Roussel
- Department of General Practice, Clermont Auvergne University, Faculty of Medicine, UPU ACCePPT, Clermont-Ferrand, France
| | - Rosa Abellana
- Departament de Fonaments Clinics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain
| | | | - Radost Assenova
- School of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria
| | - Djurdjica Kasuba Lazic
- Department of Family Medicine ‘Andrija Stampar’ School of Public Health, School of Medicine University of Zagreb, Zagreb, Croatia
| | - Peter Torsza
- School of Medicine, Semmelweis University, Budapest, Hungary
| | - Liam George Glynn
- Health Research Institute and Graduate Entry Medical School, University of Limerick, Limerick, Ireland
| | - Heidrun Lingner
- Hannover Medical School, Center for Public Health and Healthcare, Hannover, Germany
| | - Jacopo Demurtas
- Primary Care Department, Azienda Usl Toscana Sud Est, Grosseto, Italy
| | - Beata Borgström
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Sylvaine Gibot-Boeuf
- Department of General Practice, Clermont Auvergne University, Faculty of Medicine, UPU ACCePPT, Clermont-Ferrand, France
| | - Miguel Angel Muñoz
- Institut Català de la Salut, Barcelona, Spain
- Unitat de Suport a la Recerca de Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
- School of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
| |
Collapse
|
2
|
Verbovoy AF, Tsanava IA, Mitroshina EV, Sharonova LA. [Osteoprotegerin is a new marker of cardiovascular diseases]. TERAPEVT ARKH 2019; 89:91-94. [PMID: 28514407 DOI: 10.17116/terarkh201789491-94] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Osteoprotegerin (OPG) is a glycoprotein that is a representative of the tumor necrosis factor-α receptor superfamily. Information about the possible role of OPG in the development of cardiovascular diseases has begun to appear in the literature in recent years. This review discusses the role of increasing the level of OPG in the development and progression of atherosclerosis and as a consequence of coronary heart disease and chronic heart failure.
Collapse
Affiliation(s)
- A F Verbovoy
- Samara State Medical University, Health Ministry of Russia, Samara, Russia
| | - I A Tsanava
- Samara State Medical University, Health Ministry of Russia, Samara, Russia
| | - E V Mitroshina
- Samara State Medical University, Health Ministry of Russia, Samara, Russia
| | - L A Sharonova
- Samara State Medical University, Health Ministry of Russia, Samara, Russia
| |
Collapse
|